What question did this study set out to answer?

The aim is to develop a Trop2 antibody-radionuclide conjugate for both imaging and therapy in cancer treatment.

April 5, 2026

Abstract 7189: Innovative theranostic Trop2 antibody-radionuclide conjugates (ARCs) for precision medicine

Key Points

The aim is to develop a Trop2 antibody-radionuclide conjugate for both imaging and therapy in cancer treatment.
Developed a Trop2 antibody conjugated with 89Zr for imaging and 225Ac for therapeutic purposes.
Evaluated the ARC in various xenograft models including triple-negative breast cancer and non-small cell lung cancer.
Assessed tumor accumulation and tumor-to-normal tissue ratios.
The imaging ARC showed strong tumor accumulation with favorable tumor-to-normal tissue ratios.
The therapeutic ARC effectively suppressed tumor growth in xenograft models.
Preclinical development is ongoing, with an IND application targeted for 2026.

Abstract

Abstract Theranostic antibody conjugates are an emerging class of therapeutics that combines an antibody with radionuclides that can both diagnose and treat disease. We have developed a site-specific Trop2 antibody-radionuclide conjugate (ARC), incorporating 89Zr for imaging and 225Ac for therapy. The imaging ARC, leveraging the long half-life of 89Zr, demonstrates strong tumor accumulation and favorable tumor-to-normal tissue (T/N) ratios across multiple xenograft models, including triple-negative breast cancer and non-small cell lung cancer. The therapeutic ARC, carrying an alpha-emitting radionuclide, effectively suppresses tumor growth in the corresponding xenograft models. This ARC is currently in preclinical development, with an investigational new drug (IND) application planned for 2026. Citation Format: Shih-Hsien Chuang, Wei-Ting Sun, Michael Evans, Haibo Xu. Innovative theranostic Trop2 antibody-radionuclide conjugates (ARCs) for precision medicine abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7189.

AIに質問

Bookmark

Cite This Study

Chuang et al. (Fri,) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a23f5 https://doi.org/https://doi.org/10.1158/1538-7445.am2026-7189

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark